Cover Image
市場調查報告書

血液凝固凝血因子XI (血漿凝血酵素原前驅物質) :開發中產品分析

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363581
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
血液凝固凝血因子XI (血漿凝血酵素原前驅物質) :開發中產品分析 Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 52 Pages
簡介

本報告提供血液凝固凝血因子XI (血漿凝血酵素原前驅物質)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

血液凝固凝血因子XI (血漿凝血酵素原前驅物質)的概要

治療藥的開發

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):開發中的產品 - 各開發階段

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):開發中的產品 - 各治療範圍

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):開發中的產品 - 各適應症

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):企業開發中的產品

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):大學/機關開發中的產品

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

血液凝固凝血因子XI (血漿凝血酵素原前驅物質)的治療藥的開發企業

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cambryn Biologics LLC
  • eXithera Pharmaceuticals, Inc
  • Ionis Pharmaceuticals, Inc.
  • LegoChem Biosciences, Inc

藥物簡介

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):暫停中的計劃

血液凝固凝血因子XI (血漿凝血酵素原前驅物質):主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0617TDB

Summary

Global Markets Direct's, 'Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2016', provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted pipeline therapeutics.

The report provides comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
  • The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Overview
  • Therapeutics Development
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Stage of Development
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Therapy Area
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Indication
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Products Glance
  • Late Stage Products
  • Early Stage Products
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Companies
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Products under Development by Universities/Institutes
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
  • Assessment by Monotherapy/Combination Products
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Ionis Pharmaceuticals, Inc.
  • LegoChem Biosciences, Inc
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles
  • AB-012 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AB-022 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BAY-1213790 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-262084 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-654457 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • coagulation factor XI (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • coagulation factor XI (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EP-7041 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IONIS-FXIRx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Projects
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Featured News & Press Releases
  • Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
  • Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022
  • Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
  • Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
  • May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
  • Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma
  • Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
  • Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
  • Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders
  • Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Bayer AG, H2 2016
  • Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top